Skip to content
RestemRestem
  • Menu
  • Our Science
    • Our Cells
    • ULSCs
    • NK Cells
    • Compassionate Use Policy
  • Our Trials
    • COVID
    • Muscular Dystrophy
    • Autoimmune
    • Heart Failure
  • Our Company
    • Team
    • Advisors
    • Partners
    • Careers
  • Investors & Media
    • Corporate Profile
    • Publications
    • Press Releases
  • Contact
Announcements

Restem

Posted on December 4, 2019July 1, 2020 by michelleibarra

RESTEM to donate its proprietary ULSCs in an approved investigational new drug application phase I clinical study at University of Florida on Polymyositis/Dermatomyositis entitled, “LEVERAGING THE IMMUNOMODULATORY CAPACITY OF MESENCHYMAL STROMAL CELLS FOR THE THERAPY OF REFRACTORY POLYMYOSITIS AND DERMATOMYOSITIS”.

University of Murcia
3 Miami COVID-19 Patients Successfully Recovered with Stem Cell Therapy
Latest Posts
  • 14
    May
    FDA approves COVID-19 treatment after successful use of STEM CELLS from RESTEM Comments Off on FDA approves COVID-19 treatment after successful use of STEM CELLS from RESTEM
  • 08
    May
    Florida Mom Recovers From Covid-19 with Stem Cell Therapy Comments Off on Florida Mom Recovers From Covid-19 with Stem Cell Therapy
  • 08
    May
    Patient Credits Stem Cell Treatment With Saving Her Life Comments Off on Patient Credits Stem Cell Treatment With Saving Her Life
  • 07
    May
    COVID-19: Three Patients Successfully Treated with RESTEM Stem Cells Comments Off on COVID-19: Three Patients Successfully Treated with RESTEM Stem Cells
  • 07
    May
    3 Miami COVID-19 Patients Successfully Recovered with Stem Cell Therapy Comments Off on 3 Miami COVID-19 Patients Successfully Recovered with Stem Cell Therapy
Categories
  • Announcements (4)
  • News (5)
Copyright 2023 © Restem
  • Our Science
    • Our Cells
    • ULSCs
    • NK Cells
    • Compassionate Use Policy
  • Our Trials
    • COVID
    • Muscular Dystrophy
    • Autoimmune
    • Heart Failure
  • Our Company
    • Team
    • Advisors
    • Partners
    • Careers
  • Investors & Media
    • Corporate Profile
    • Publications
    • Press Releases
  • Contact